ORIC Pharmaceuticals: The Long View
What the filings say about its story, dilution and cash runway.
This page is information, not investment advice.
Sources used most:
- 10-K FY2025, filed Feb 23, 2026
- 10-Q Q2 2026, filed Aug 3, 2026
- Q2 2026 results release, Aug 3, 2026
1. In one paragraph
Last updated Oct 27, 2026. Reflects the 10-K FY2025 and the 10-Q for Q2 2026.
ORIC is a clinical-stage cancer drug developer. It has no products on sale, has never generated revenue and reports one operating segment; it pays for its work by selling shares (10-Q, note 1). Its two drugs are rinzimetostat, a pill in a Phase 3 trial (a large trial intended to support approval) for advanced prostate cancer, and enozertinib, a pill in Phase 1b (an early trial of safety, dose and first signs of activity) for lung cancer with mutations in EGFR, a protein involved in cell-growth signalling.
- In 2025 it recorded $143.0M of operating expenses: research and development $109.8M (77%) and general and administrative $33.2M (23%). Outside R&D costs were $25.1M for rinzimetostat and $30.8M for enozertinib. Other income, net, of $13.5M brought the net loss to $129.5M (10-K, MD&A).
- ORIC licensed rinzimetostat worldwide from Mirati (now part of Bristol Myers Squibb) with no milestones or royalties.
- It licensed enozertinib from Voronoi for all markets except Greater China, with milestones and royalties owed (10-Q, note 3).
2. Story so far
Last updated Oct 27, 2026. Reflects filings and releases through Oct 23, 2026.
In short: ORIC licensed both of its current drugs in 2020 and has funded their development through private placements, a direct stock sale to Pfizer and at-the-market share offerings; since 2022 its share count, including pre-funded warrants (rights bought upfront that need only $0.0001 a share to exercise), nearly tripled. ORIC announced Phase 3 initiation for its lead drug rinzimetostat on July 14, 2026, and ORIC plans a Phase 3 trial of enozertinib in the first half of 2027. Stock Analysis reports that ORIC fell 32% on Oct 26, 2026, following Johnson & Johnson’s Oct 25 announcement of early data for a rival prostate cancer drug.
| Date | Milestone | Source |
|---|---|---|
| Aug 3, 2020 | Licenses the PRC2 programme (PRC2 is a protein complex that regulates gene activity) that became rinzimetostat from Mirati for 588,235 ORIC shares; no milestones or royalties | 10-Q Q2 2026, note 3 |
| Oct 19, 2020 | Licenses enozertinib from Voronoi for $5.0M plus 283,259 shares; up to $111M of development and regulatory milestones | 10-Q Q2 2026, note 3 |
| Jul 8, 2021 | Sells 2.6M shares at $19.25 ($50.0M) through its at-the-market (ATM) programme | 10-K FY2021 |
| Dec 21, 2022 | Pfizer buys $25.0M of stock at $4.65 alongside a trial collaboration on ORIC-533; cash runway “into 1H 2025” | 8-K |
| Jun 26, 2023 | $85.0M private placement at $7.00; runway “into late 2025” | 8-K |
| Jan 2024 | ★ First rinzimetostat Phase 1b data (Jan); $125.0M private placement at $10.00 (Jan 22); runway “into late 2026” | 10-Q Q2 2026; 8-K |
| May 23, 2025 | $125.0M private placement at $6.50, partly as pre-funded warrants; runway “into the second half of 2027” | 8-K |
| Aug 12, 2025 | Closes its discovery research group, cutting about 20% of staff | 8-K |
| Mar 31, 2026 | ★ Picks 400 mg rinzimetostat with darolutamide as the Phase 3 dose; 84% of patients alive without scan-confirmed progression at five months | 8-K; Q1 release |
| Jul 14, 2026 | ★ Announces initiation of Himalayas-1, a Phase 3 trial of about 600 patients; Bayer supplies darolutamide free | Release |
| Oct 23, 2026 | Enozertinib data at the ESMO congress: investigators assessed confirmed tumour responses in 21 of 25 response-evaluable first-line patients (receiving their first treatment for advanced disease; 84%; 26 patients treated); Phase 3 trial Redwood-1 planned for 1H 2027 | 8-K |
| Oct 26, 2026 | ★ Stock Analysis reports a 32% fall to $8.96 following J&J’s announcement of early data for its rival drug JNJ-6143. Start of our coverage: ORIC falls 32% after J&J shows early data for a rival prostate cancer drug | J&J release; Stock Analysis |
3. Latest quarter: did the story change?
Last updated Oct 27, 2026. Reflects Q2 2026 (10-Q filed Aug 3, 2026) and the Oct 23 8-K. Q3 results are expected in mid-November; ORIC has not announced the date.
Bottom line: According to its filings, ORIC started its first Phase 3 trial and kept its cash-runway estimate, but its quarterly loss widened as trial spending rose, its second drug’s Phase 3 start is now planned for 1H 2027, and a rival’s early data has since added a competitive question.
| Driver | Last quarter → this quarter | Management: before → now | Signal |
|---|---|---|---|
| Rinzimetostat Phase 3 | Phase 3 dose chosen (Mar 31) → Himalayas-1 initiation announced (Jul 14) | Guided for 1H 2026 (May 4) → announced Jul 14; initiation date not given (the Bayer supply agreement is dated Jul 7) | Unchanged |
| Enozertinib | Phase 1b enrolling → 84% confirmed response rate in 25 first-line patients with atypical EGFR mutations (Oct 23) | Potential initiation of registrational trials for both drugs “in 2026” (Nov 13, 2025) → Redwood-1 in 1H 2027 (Oct 23) | Watch |
| Spending | Net loss Q1 $35.8M → Q2 $41.5M; R&D $31.4M → $36.3M (rinzimetostat outside costs $12.1M → $16.0M) | R&D to “increase substantially” (10-K, Feb 23) → same wording (10-Q, Aug 3) | Worse |
| Cash and runway | Cash and investments $419.7M (Mar 31) → $387.6M (Jun 30) | “Into 2H 2028” (May 4) → “into 2H 2028” (Aug 3) | Unchanged |
| Competition | J&J reported a 75% tumour response rate (12 of 16 measurable patients) for JNJ-6143 (Oct 25); Stock Analysis reports ORIC fell 32% (Oct 26) | We found no ORIC statement on the J&J data → none found (Oct 26) | Watch |
Sources: Q1 2026 release, Q2 2026 release, Q3 2025 release, 10-Q Q1 2026, 10-Q Q2 2026, 8-K, Oct 23, J&J release.
Unresolved questions: when Himalayas-1 reads out (ORIC has said only that its cash should last beyond that readout), how much spending rises with two Phase 3 trials, and whether J&J tests its drug in the earlier-stage patients ORIC is targeting.
4. Buybacks vs real dilution (5 years)
Last updated Oct 27, 2026. Reflects the equity statements in the 10-K FY2023, 10-K FY2025 and 10-Q Q2 2026.
Dilution in one line: common shares plus pre-funded warrants rose 174% from Dec 31, 2021 to Jun 30, 2026, about 25.1% a year compounded. If you owned 1% of ORIC at the end of 2021, you’d own about 0.36% on Jun 30, 2026 without buying more (our calculation)1. None of the new shares were offset by buybacks. Our scale: High (over 3% a year).
Our rule of thumb: under 1% a year low, 1–3% moderate, over 3% high.
Change in the period Total since Dec 31, 2021 Part year
Shares outstanding at period end (all classes): 39.4M on Dec 31, 2021, 108.1M on Jun 30, 2026, +174.2% (our calculation). A bar below zero means the count fell (net buybacks).
Common shares plus pre-funded warrants (prepaid rights to shares at $0.0001 each), from the author's bridge (10-K and 10-Q equity statements); pre-funded warrants have no standard XBRL tag.
| Period end | Shares outstanding | Change | Buybacks (fiscal year) | Stock-based pay (fiscal year) | Stock pay as % of revenue |
|---|---|---|---|---|---|
| H1 2026 (Jun 30, 2026) | 108.1M | +5.0% | — | — | — |
| FY2025 (Dec 31, 2025) | 103.0M | +45.1% | — | $25M | — |
| FY2024 (Dec 31, 2024) | 71.0M | +23.1% | — | $20M | — |
| FY2023 (Dec 31, 2023) | 57.7M | +27.9% | — | $15M | — |
| FY2022 (Dec 31, 2022) | 45.1M | +14.4% | — | $14M | — |
| FY2021 (Dec 31, 2021) | 39.4M | — | — | $13M | — |
Shares outstanding from the balance sheets in the company's 10-K and 10-Q filings; buybacks (cash spent) and stock-based pay from its 10-Ks, via SEC EDGAR.
How we calculated this
Pre-funded warrants are prepaid rights to shares at $0.0001 each; ORIC includes them in its per-share loss count. On common shares alone, the rise is 163%2.
| Bridge (millions of shares, incl. pre-funded warrants) | 2022 | 2023 | 2024 | 2025 | H1 2026 | Total |
|---|---|---|---|---|---|---|
| Start of period | 39.4 | 45.1 | 57.7 | 71.0 | 103.0 | 39.4 |
| Private placements and direct sales (incl. pre-funded warrants) | 5.4 | 12.1 | 12.5 | 19.2 | – | 49.3 |
| At-the-market sales | – | – | – | 11.8 | 4.7 | 16.5 |
| Stock pay and employee plans (options, restricted stock units, share purchase plan) | 0.3 | 0.5 | 0.8 | 1.0 | 0.4 | 2.9 |
| Acquisitions or convertible notes | 0 | 0 | 0 | 0 | 0 | 0 |
| Buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| End of period | 45.1 | 57.7 | 71.0 | 103.0 | 108.1 | 108.1 |
Totals use unrounded filing figures. Exercising pre-funded warrants (2.86M in 2024, 0.64M in 2025) moved shares from warrants to common stock; ORIC withheld 47 shares in those exercises. 4.46M pre-funded warrants were outstanding at Jun 30, 2026 (10-Q, note 8).
Prices paid and received:
| Period | Shares bought back | Average price paid | Spent | Shares sold for cash | Average price received | Raised | Sources |
|---|---|---|---|---|---|---|---|
| 2022 | — | — | — | 5.38M | $4.65 | $25.0M | 10-K FY2022: Pfizer direct sale |
| 2023 | — | — | — | 12.14M | $7.00 (our calculation) | $85.0M | 10-K FY2023: 9.29M shares at $7.00 and 2.86M pre-funded warrants at $6.9999 |
| 2024 | — | — | — | 12.50M | $10.00 | $125.0M | 10-K FY2024: private placement |
| 2025 | — | — | — | 31.01M | $7.88 (our calculation) | $244.4M | 10-K FY2025: 19.23M shares and pre-funded warrants at $6.50 ($125.0M); 11.78M ATM shares at a $10.13 average ($119.4M, our calculation)3 |
| 2026 to date (Jan 1–Jun 30) | — | — | — | 4.70M | $12.96 | $60.9M | 10-Q Q2 2026, note 1 and cash flow statement |
ORIC has sold shares for cash every year since 2022 (private placements, a Pfizer direct sale and at-the-market sales) and has never bought any back. Averages are derived (our calculation)4.
Basis and details
- Prices are per share; ORIC has not split its stock since listing in April 2020. Raised is gross proceeds before costs.
- Employee option exercises and share-purchase-plan sales are excluded. ORIC has never bought back stock.
- No sale after Jun 30 had been disclosed by Oct 27; the share count was 103.65M on Jul 27 (10-Q, cover).
- For reference, Stock Analysis reports a $9.00 closing price on Oct 27, 2026 (Stock Analysis).
| Stock-based pay | 2022 | 2023 | 2024 | 2025 | H1 2026 |
|---|---|---|---|---|---|
| $M | 14.5 | 15.2 | 20.2 | 25.0 | 14.0 |
| % of operating expenses (our calculation; ORIC has no revenue) | 16% | 14% | 14% | 18% | 16% |
Employee awards already granted are a further source of new shares. In June 2026 shareholders approved lowering the plan’s annual top-up rate from 5% to 4% while removing its 2.66M-share annual cap, so the annual addition can be larger.
Employee awards and the share plan
- At Jun 30, 2026, 17.15M options (average exercise price $6.92) and 1.12M restricted stock units (awards that deliver shares when vesting conditions are met) were outstanding.
- Since June 2026, the plan’s yearly automatic top-up is 4% of outstanding shares (was 5%), without the former 2.66M-share limit (8-K, Jun 22).
5. Profit vs cash (latest FY and TTM)
Last updated Oct 27, 2026. Reflects the 10-K FY2025, the 10-Q Q2 2025 and the 10-Q Q2 2026. ORIC reports no adjusted profit measure.
ORIC’s cash outflow is close to its net loss; stock-based pay is the main non-cash cost.
| $M | FY2025 | Trailing twelve months (TTM) to Jun 30, 2026 (our calculation)5 |
|---|---|---|
| Net loss | −129.5 | −140.4 |
| Adjusted metric | Not reported | Not reported |
| Operating cash flow | −111.0 | −111.6 |
| Capital spending | −0.7 | −0.6 |
| Free cash flow (our calculation)6 | −111.7 | −112.3 |
The items between the loss and the cash flow are small. Grouped by what each means for future profit and cash:
Helps future profit or cash:
- None identified.
Hurts future profit or cash:
- Stock-based pay added back $25.0M in 2025 ($25.9M TTM): Not a cash cost, but it is a cost in the loss and it adds shares (see section 4).
One-off / no lasting effect:
- Lower payables and accrued costs used $7.2M of cash in 2025; prepaid and other assets released $1.8M (10-K, cash flow statement): A timing difference between profit and cash.
- Interest income accrued on discounted Treasury bills ($2.3M in 2025): A timing difference: counted in the loss before the cash arrives at maturity.
The raw reconciling items
- Stock-based pay added back $25.0M in 2025 ($25.9M TTM).
- Lower payables and accrued costs used $7.2M of cash in 2025; prepaid and other assets released $1.8M (10-K, cash flow statement).
- Interest income accrued on discounted Treasury bills ($2.3M in 2025) is counted in the loss before the cash arrives at maturity.
Funding: how long without new money? (our calculation; as of Jun 30, 2026, the latest filed balance sheet)
Funding details
- ORIC expects R&D to “increase substantially” as trials advance, which is why its estimate is shorter than our past-rate path.
- ORIC has no debt or convertible notes, and its 10-Q discloses no credit lines.
- ATM programme: $200.0M, opened Feb 26, 2026 with Jefferies (8-K). About $159M remained at Jun 30 (our calculation)8.
- Exercising the 4.46M pre-funded warrants would bring in almost no cash ($0.0001 each).
- This is based on past cash flow; spending plans can change it.
Extends the runway:
- None committed. There is no credit line, and no share sale after Jun 30 had been disclosed by Oct 27.
Shortens the runway:
- None (no debt, maturities or covenants).
Conditional:
- The at-the-market programme (about $159M left), which brings in cash only if ORIC sells shares; and Voronoi milestones of up to $111M, which ORIC would owe only if development milestones are met, with no dates disclosed.
Cash path (our calculation; an illustration, not a forecast):
At the past rate and with known items, cash would fall below zero in Q4 2029; the company itself says its cash will last into the second half of 2028 (10-Q), because it expects research and development spending to “increase substantially”.
Illustration, not a forecast.
Ending cash (cash, equivalents and marketable securities) Known item Raising window (under a year of usual spending left) Would need new money
| Quarter | Starting cash | Usual spending | Known items | Ending cash | Sources / notes |
|---|---|---|---|---|---|
| Q3 2026 | +387.6 | −28.1 | 0.0 | +359.5 | No share sale after Jun 30 disclosed by Oct 27 |
| Q4 2026 | +359.5 | −28.1 | 0.0 | +331.4 | |
| Q1 2027 | +331.4 | −28.1 | 0.0 | +303.4 | |
| Q2 2027 | +303.4 | −28.1 | 0.0 | +275.3 | |
| Q3 2027 | +275.3 | −28.1 | 0.0 | +247.2 | |
| Q4 2027 | +247.2 | −28.1 | 0.0 | +219.2 | |
| Q1 2028 | +219.2 | −28.1 | 0.0 | +191.1 | |
| Q2 2028 | +191.1 | −28.1 | 0.0 | +163.0 | |
| Q3 2028 | +163.0 | −28.1 | 0.0 | +135.0 | ORIC’s own runway estimate ends “into 2H 2028” |
| Q4 2028 | +135.0 | −28.1 | 0.0 | +106.9 | Less than a year of usual spending left. |
| Q1 2029 | +106.9 | −28.1 | 0.0 | +78.9 | Less than a year of usual spending left. |
| Q2 2029 | +78.9 | −28.1 | 0.0 | +50.8 | Less than a year of usual spending left. |
| Q3 2029 | +50.8 | −28.1 | 0.0 | +22.7 | Less than a year of usual spending left. |
| Q4 2029 | +22.7 | −28.1 | 0.0 | −5.3 |
Amounts in $M.
At the past rate and with known items, cash would fall below zero in Q4 2029; the company itself says its cash will last into the second half of 2028 (10-Q), because it expects research and development spending to “increase substantially”. Our path assumes flat spending at the past rate. Companies usually raise money well before that; quarters with less than a year of usual spending left are shaded.
What the cash path counts:
- Usual spending: about −$28.1M a quarter, held flat.
- Known items: none dated. ORIC has no debt, no acquisitions and no minimum purchase commitments.
How we calculated this
Usual spending is TTM free cash flow (−$112.3M, Q3 2025–Q2 2026) ÷ 4 ≈ −$28.1M a quarter, held flat. Calculations use unrounded amounts (starting cash $387.560M, quarterly spending −$28.0645M); displayed values are rounded to $0.1M. Starting cash is cash, cash equivalents and investments at Jun 30, 2026. ORIC has disclosed no dated known items: no debt, no acquisitions and no minimum purchase commitments (10-K, MD&A). Lease payments and ordinary trial and manufacturing costs are already in past free cash flow, so they are not added. Capital spending is small ($0.6M TTM, $0.7M in 2025, $1.2M in 2024) and ORIC has disclosed no capital-spending plan. Not included: Voronoi milestones of up to $111M, with no dates disclosed.
6. Customer and contract exposure
Last updated Oct 27, 2026. Reflects the 10-K FY2025, the 10-Q Q2 2026 and releases through Oct 23, 2026.
ORIC has no customers or revenue. Its exposure lies in two licences (rinzimetostat is royalty-free from Mirati; enozertinib carries milestones and royalties to Voronoi) and in drug supply from Bayer and J&J, which also develops a rival prostate cancer drug.
Licence and supply contracts
| Contract | Signed | Terms | Source |
|---|---|---|---|
| Mirati (Bristol Myers Squibb) licence: rinzimetostat | Aug 3, 2020 | Worldwide, royalty-free; paid in shares. Mirati may end it if ORIC challenges the patents or stops development; ORIC may end it on notice | 10-Q, note 3 |
| Voronoi licence: enozertinib | Oct 19, 2020 | All markets except Greater China. Up to $111M of development and regulatory milestones and $225M of sales milestones, plus royalties. ORIC paid $5.0M upfront plus 283,259 shares, and a further $5.0M development milestone in Q3 2022 | 10-Q, note 3 |
| Bayer supply: darolutamide | May 14, 2024; Jul 7, 2026 (Phase 3) | Free supply; Bayer gets no rights to rinzimetostat | 10-Q, note 3 |
| J&J supply: apalutamide and amivantamab | Jul 10 and Aug 29, 2024 | Supply for combination trials; ORIC keeps all rights | 10-Q, note 3 |
| Cancer Research UK: ORIC-259 (early-stage) | Oct 5, 2026 | The charity funds and runs development through Phase 1/2; ORIC can take the rights back afterwards, with milestones and royalties owed to the charity | Release |
- J&J supplies ORIC’s trials and also develops JNJ-6143, a rival prostate cancer drug (J&J release).
- ORIC’s issued US patents on rinzimetostat as a compound are expected to expire in 2039, before any extension (10-K, Item 1).
7. What to watch
Last updated Oct 27, 2026. Reflects the 10-Q for Q2 2026, the Q2 2026 release, the Oct 23 8-K and the Q3 2025 release (last year’s results date).
| Date | Item | Source |
|---|---|---|
| Mid-Nov 2026 (not yet announced) | Q3 2026 results. Last year’s Q3 results came out on Nov 13, 2025; MarketBeat estimates Nov 12, 2026 (reported, not confirmed by ORIC) | Q3 2025 release; MarketBeat |
| 2H 2026 | Rinzimetostat programme update; enozertinib data in first-line exon 20 patients, alone and with amivantamab | Q2 2026 release |
| 1H 2027 | Planned start of Redwood-1, the Phase 3 trial of enozertinib (about 360 patients) | 8-K, Oct 23 |
| 2H 2028 | End of ORIC’s own cash-runway estimate. ORIC says this is after the expected main readout of Himalayas-1, but has not given a readout date | Q2 2026 release |
Valuation at each update
| Update | Close | Market value | EV | P/S | EV/sales | P/E | P/FCF | Revenue growth | FCF margin | Net cash (debt) | Basis |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 27, 2026 | $8.96 (Oct 26) | $929M | $541M | n/m | n/m | n/m | n/m | n/m | n/m | $388M | 12 months to Jun 30, 2026; pre-revenue |
Our calculation from each update's filings (latest at the newest update: 10-Q for the quarter to Jun 30, 2026, filed Aug 3, 2026); not investment advice. n/m = not meaningful (e.g. negative earnings). Hover a heading for its definition. Oct 27, 2026 row: Corrected Oct 31, 2026: market value now uses common shares outstanding (103.7 million on the 10-Q cover page, Jul 27, 2026), our standard basis, instead of 108.1 million shares including pre-funded warrants; market value $929M (was $969M) and enterprise value recalculated. Price and date unchanged.
Notes and calculations
-
Our calculations: growth = (108.100 ÷ 39.430 − 1) × 100 ≈ 174%; annual rate = [(108.100 ÷ 39.430)^(1 ÷ 4.5) − 1] × 100 ≈ 25.1%; remaining ownership = 1% × 39.430 ÷ 108.100 ≈ 0.36% (39.4M ÷ 108.1M). ↩
-
103.6M ÷ 39.4M − 1. ↩
-
$244.4M cash-flow total − $125.0M. ↩
-
Gross proceeds ÷ shares and pre-funded warrants sold. ↩
-
FY2025 − H1 2025 + H1 2026. ↩
-
Operating cash flow + capital spending. ↩
-
$387.6M ÷ $112.3M. ↩
-
$200.0M − ($60.9M H1 gross − about $20.3M sold under the earlier prospectus through Feb 23, 2026). The $20.3M is our calculation: $139.7M cumulative gross proceeds under the earlier prospectus − $119.4M FY2025 gross proceeds. ↩
Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.
About ORIC Pharmaceuticals: Website (external site)Investor relations (external site)SEC filings (external site)